Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06567782
Title A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer (AZUR-4)
Acronym AZUR-4
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors GlaxoSmithKline
Indications
Therapies
Age Groups: adult | senior
Covered Countries GBR | ESP | BEL

Facility Status City State Zip Country Details
GSK Investigational Site Aalst 9300 Belgium Details
GSK Investigational Site Bonheiden 2820 Belgium Details
GSK Investigational Site Bruxelles 1070 Belgium Details
GSK Investigational Site Bruxelles 1200 Belgium Details
GSK Investigational Site Gent 9000 Belgium Details
GSK Investigational Site Leuven 3000 Belgium Details
GSK Investigational Site LiEge 4000 Belgium Details
GSK Investigational Site Liege 4000 Belgium Details
GSK Investigational Site Roeselare 8800 Belgium Details
GSK Investigational Site Barcelona 8035 Spain Details
GSK Investigational Site Madrid 28222 Spain Details
GSK Investigational Site Glasgow G12 0YN United Kingdom Details
GSK Investigational Site Leeds West Yorkshire LS9 7TF United Kingdom Details
GSK Investigational Site London NW1 2PG United Kingdom Details
GSK Investigational Site Sutton SM2 5PT United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field